Advertisement
UK markets close in 4 hours 45 minutes

  • FTSE 100

    8,253.30
    +12.04 (+0.15%)
     

  • FTSE 250

    20,820.84
    +210.50 (+1.02%)
     

  • AIM

    774.30
    +4.88 (+0.63%)
     

  • GBP/EUR

    1.1811
    +0.0013 (+0.11%)
     

  • GBP/USD

    1.2785
    +0.0024 (+0.19%)
     

  • Bitcoin GBP

    43,154.57
    -1,877.90 (-4.17%)
     

  • CMC Crypto 200

    1,142.62
    -66.08 (-5.48%)
     

  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     

  • DOW

    39,308.00
    -23.90 (-0.06%)
     

  • CRUDE OIL

    83.93
    +0.05 (+0.06%)
     

  • GOLD FUTURES

    2,373.30
    +3.90 (+0.16%)
     

  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

  • HANG SENG

    17,799.61
    -228.67 (-1.27%)
     

  • DAX

    18,606.94
    +156.46 (+0.85%)
     

  • CAC 40

    7,725.21
    +29.43 (+0.38%)
     
Money:

What the new Labour government means for your money

Now that the dust has settled on the election we can take stock of what a Labour win will mean for your finances

Blackstone selling Japan drugmaker Alinamin to MBK Partners

Reuters
·1-min read
Signage is seen outside The Blackstone Group headquarters in Manhattan, New York

TOKYO (Reuters) - Blackstone and MBK Partners said on Wednesday the U.S. private equity firm is selling Japanese drugmaker Alinamin Pharmaceutical to the North Asian buyout fund.

The deal size would be 350 billion yen ($2.17 billion), a source said on Tuesday, however neither Blackstone nor MBK in their separate statements disclosed the transaction value.

Blackstone acquired Alinamin in 2020 from Takeda Pharmaceutical in what it said was the largest healthcare transaction in Japan.

Blackstone will re-invest an indirect, minority stake in Alinamin upon the closing of the transaction, it said.

($1 = 161.5100 yen)

(Reporting by Anton Bridge; Editing by Muralikumar Anantharaman)